

Testis Cancer

Demographics

1% male tumours in the UK
5:100,000 male population per year
Lifetime male risk 1:500 (normally descended testes)
Incidence rising ? why
20-30 (NSGCT) 30-40 (Seminoma)
Northern Europe/ USA
Whites > Blacks
US Black > African Black

Aetiology

Undescended Testis

10% GCT arise in undescended testes
RR of GCT with UDT is 4-10 (much higher in earlier studies with higher numbers of non-operated intra-abdominal testes)
Seminoma more common cf. NSGCT (60% vs. 40%)
Risk of testis ca:
 Normal 1:500
 Unilateral UDT 1:125
 Bilateral UDT 1:45
One previous testis cancer:
 Normally descended contralateral testis 1:250
 Contralateral UDT 1:4

Histological evidence suggests ↓ spermatagonia and seminiferous tubules with interstitial fibrosis between 2 and 3 years (Cooper 1929; Mengel and Hedinger 1970s)

Does orchidopexy reduce risk of subsequent cancer?

Controversial

Some case-control studies suggest that orchidopexy before age of ten reduced risk of cancer (Swerdlow 1997). Some studies however suggest that risk of cancer is actually greater in testes that have undergone orchidopexy (Forman D, BMJ, 1994). No evidence yet of improved risk profile if orchidopexy before age of 2, although widely recommended (between 18 months and 2 years ideally). Most complete evidence to date suggests that testes requiring orchidopexy have an increased risk compared with normally descended testes, but that the risk can be reduced provided orchidopexy performed before the age of 13 (Petterson NEJM 1997)

Risk factors for testis cancer

Caucasian

UDT

Unilateral	4x
Bilateral	10x
Contralateral GCT	8x
1 st degree male relative	6x
Subfertility	2x
Klinefelter's	
Kallman's	
Prenatal oestrogen exposure	

Congenital abnormalities

Klinefelter's Syndrome (47XXY)

De novo genetic event
Tall and Thin
Gynaecomastia
Small firm testicles
Elevated gonadotrophins

Kallman's Syndrome

Sporadic/familial
Defective GnRH release
Delayed puberty
Anosmia
Long limbs

Familial Risk

<2.2% of cases with positive family history

Brother of Index = RR 6-10

Father/Son of Index = RR 4-6

Dizygotic twin = RR 36

Monozygotic twin = RR 77

Xq27 locus may be responsible in up to ~25% cases

Pre-natal oestrogen exposure

Mouse studies = increased incidence with prenatal exposure to E

Human studies = Trial of DES to prevent abortion resulted in higher no. with testicular abnormalities

Testicular cancer rates higher in hyperemesis, first pregnancies and twins (all associated with higher in utero oestrogen exposure)

Male fish feminisation with oestrogenic pollutants from food packaging (bisphenols)

Previous testicular GCT

Risk of contralateral CIS = 5%

15-year risk of contralateral GCT (from SEER database Fossa 2005 n = 29,000)
 synchronous (defined as within 2 months of diagnosis) – 0.6%
 metachronous (> 2 months) 1.0%

Overall risk = 1.6%

No evidence:

- Vasectomy
- Genital abnormality (hypospadias, varicocele, PPV)
- Trauma - associated with increased risk in retrospective studies but almost certainly due to recall bias
- Smoking
- Alcohol consumption
- Tight trousers/underwear

Pathology

Germ cell tumours account for 95%. Leydig-cell (3%) and sertoli-cell (~1%) and rare others account for rest. Metastasis rare (lymphoma, prostate, kidney in order)

Totipotent germ cells can differentiate to spermatocytic tissue (seminoma) or somatic elements (endoderm, ectoderm or mesoderm = teratoma) or trophoblast or yolk sac elements:

Seminoma - divided into classic, spermatocytic and anaplastic.

NSGCT - WHO classification superseded UK classification. Rigid definition of teratoma as differentiated somatic elements. Undifferentiated tissue therefore embryonal.

WHO	British
Mature teratoma	Teratoma differentiated
Immature teratoma	Malignant teratoma intermediate
Embryonal carcinoma	Malignant teratoma undifferentiated
Choriocarcinoma	Malignant teratoma trophoblastic
Yolk sac tumour	Yolk sac tumour
Mixed	Mixed

Seminoma

~ 60-70% all tumours

Classic and anaplastic tumours present at 35-55 years; Spermatocytic most common tumour over 60 years.

Classic: well circumscribed homogenous firm white tumour. Uniform cells with clear cytoplasm and lymphocytic infiltrate within fibrous septa.

Anaplastic: similar to classic but increased numbers of mitoses and no lymphocyte infiltrate.

Spermatocytic: Older men. Almost always benign - one case of malignant spermatocytic seminoma to date. Polymorphic cells; small ones resemble spermatocytes. No ITGCN. No IHC PLAP staining (cf. classic band ITGCN)

Markers: 10% have elevation in BHCG due to small numbers of syncytiotrophoblasts.
PLAP elevated in 90% classic/anaplastic

NSGCT

~ 25-35% all tumours

Mature teratoma: heterogenous tumour composed of varying elements of fully differentiated tissue; endoderm (mucus secreting glands), ectoderm (stratified squamous and neural epithelium) and mesoderm (bone, cartilage, muscle). Least common, usually seen in children. Benign growth but may harbour areas of reduced differentiation. Markers: AFP in 20-25% due to hepatoid differentiation

Immature teratoma: Varying degrees of maturity present; malignant degeneration may also be seen (sarcoma, scc, adeno). Markers: AFP in 20-25% due to hepatoid differentiation

Embryonal: 20-30 years. Sheets of immature cells arranged in solid, tubular or papillary patterns. Macroscopically variegated with fleshy appearance. Usually seen in combination with other elements, especially chorio and yolk sac.

Markers: pure embryonal = no elevation, but usually BHCG and AFP (50% AFP, 50% BHCG)

Choriocarcinoma: Highly malignant. Identifiable syncytiotrophoblast (**synthesises** BHCG/ syncytium (multiple nuclei)) and cytotrophoblasts.

Markers: BHCG raised in 99% of cases

Yolk-Sac Tumours: Pure form may be seen in children < 3 years old, but usually in mixed form. Microscopically solid, papillary and microcystic forms. Markers: AFP almost always raised

Intratubular Germ Cell Neoplasia (ITGCN)

Also carcinoma in-situ (CIS) and testicular intraepithelial neoplasia (TIN)

100% of cases of GCT have adjacent ITGCN

Large irregular nuclei with coarse chromatin and prominent nucleoli

50% progression to GCT at 5 years (Burke 1998)

Virtually all develop into GCT by 10 yrs (Skakkebaek 1981; Bettochi 1994)

Diagnosed by random stab biopsy – sensitivity approx 90% presumably due to field change

Biopsies must be sent in Bouins solution. Staining for PLAP makes diagnosis

Risk of contralateral CIS in established testis cancer:

Normal contralateral testis - 1 in 20 (5%)

< 12ml, < 30 yrs, previous UDT – 1 in 3 (33%)

Treatment: RT(20Gy in 10 fractions) - patients usually rendered infertile. Most retain hormone function. ChemoRx not effective for ITGCN.

Molecular Biology

Chromosomal abnormalities universal in GCT

ITGCN usually tetraploid; GCT normally triploid

Abnormalities of short arm of chromosome 12 (12p) seen in almost all cases of testis cancer: **80% have are triploid (isochromosome)** for 12p; remainder have multiple 12p fragments on other chromosomes

i(12p) late event – not usually seen in ITGCN

Genetic linkage studies in families with testis cancer suggest that Xp27 locus on long arm of X chromosome also important.

Investigation

Markers

Elevated tumour markers seen in ~50% testicular tumours: 5-10% seminomas (always BHCG); 90% NSGCT.

Alpha feto-protein (AFP)

Produced by yolk-sac elements

Half-life 5-7 days

Raised levels in 60% NSGCT; also seen in liver, lung, stomach and pancreas cancer

Beta subunit human chorionic gonadotrophin (BHCG)

Produced by syncytiotrophoblasts

Half-life 24 hours

HCG has alpha and beta subunits: alpha subunit identical to subunits of LH, FSH & TSH; beta subunit specific to HCG.

Very high BHCG may activate LH/FSH/TSH receptors – can present with thyrotoxicosis and gynaecomastia (T converted to E by peripheral aromatase)
Elevated BHCG in 55% NSGCT and 20% seminoma; also secreted by liver, lung, stomach and pancreas tumours, and marijuana smokers.

Unlike AFP may also be elevated in urological cancers (renal and bladder)

NB. Very high levels of BHCG found in choriocarcinoma. May bleed after chemotherapy – should always perform a CT head in these patients to exclude brain mets

Lactate dehydrogenase (LDH)

Non-specific but has prognostic significance.

Raised in 60% of NSGCT and 80% seminoma

Ultrasound

7-10Mz linear array transducer

Very high sensitivity

Intratesticular cysts usually < 1cm – not considered pre-malignant (Berger 1998)

Testicular microcalcification

Multiple small echogenic foci on high resolution USS (7-10 Mhz linear array transducer); At least 5 1-3mm foci on one testicular image generally regarded as diagnostic

TM is definitely **associated** with testicular GCT: In symptomatic patients in whom a testicular tumour is found on USS, TM is present in 23-73%.

Two unresolved questions regarding TM:

Does TM denote the presence of CIS?

The only way to definitively answer this question is to biopsy patients with and without TM. Only small studies have addressed this question in the following groups.

- Asymptomatic – Schering 2002; 0/8 patients with TM had CIS
- Infertility – von Ekardstein 2001; 2/11 patients with TM had CIS
- Contralateral GCT - Schering 2002; 7/9 patients with TM had CIS

NB. Diagnosis of CIS requires careful preparation, preservation in Bouin's solution, and immunostaining with PLAP

Does TM predict the development of GCT?

No studies have addressed long-term follow-up of TM. There are 12 isolated case reports of the development of GCT in a patient with prior TM. Of these, 8 (75%) were in atrophic testes, 2 were in apparently normal testes, and 2 were not recorded. Until a large study of long term follow-up is reported, we can only speculate based on observational data – Recent data from DeCastro 2008 – 5 yr follow-up (of patients in Peterson study below) showed no difference in the incidence of cancer compared with normal patients.

Largest study of TM in asymptomatic healthy male population (US army recruits) 1504 males had scrotal US. Overall 5.6% prevalence; much higher in blacks (14.1%) compared with whites (4%). Compared with quoted incidence of 3-5 cases per 100,000 men, ~1000 fold less common, and incorrect race bias. Study criticized because should have been compared with lifetime risk of testicular GCT (1:500), but still 250x more common.

Testicular biopsy is not without its complications – bleeding, testicular atrophy, possible infertility etc. Also very high cure rates for patients with stage I make surveillance appropriate

Thus current recommendations (EAU 2010):

All asymptomatic patients with TM – testicular self-examination only

Biopsy warranted in patients < 40 yrs old with contralateral GCT and:

- History of maldescent
- Atrophy (volume < 12 ml)
- Subfertility

Testis biopsy

Not 90-100% sensitive as previously thought

Orchidectomy specimens with mapping

- 72% co-association of GCT with ITGCN
- 60% focal ITGCN

CXR

Excludes high volume pulmonary disease – oncological emergency

Dipstick urine for pregnancy test fastest way of detecting tumour

Computed Tomography

Chest/Abdo/Pelvis for staging

Nodes > 10mm considered positive for nodal metastasis: excised masses < 2cm negative for mets in 30% (Donohue 1995)

If BHCG high CT brain imperative as trophoblastic elements can cause catastrophic bleeding after ChemoRx

MRI

No better for staging than CT, but improves imaging of great vessels when RPLND contemplated

Also reduces radiation exposure for follow-up protocols – not widespread use at present

PET

Limited role

Recent evidence suggest a PET scanning a valuable tool in determining the presence of cancer in patients with residual masses after chemoRx for stage IIC seminoma. ≥ 3 cm PET scanning = 80% sensitive and 100% specific viable tumour (SEMPET study De Santis 2004).

Staging

Table 2 Royal Marsden Hospital staging of testis cancer

Stage	
I	No evidence of metastasis
IM	Rising concentrations of serum markers with no other evidence of metastasis
II	Abdominal node metastasis
● A	<2 cm in diameter
● B	2–5 cm in diameter
● C	>5 cm in diameter
III	Supra-diaphragmatic nodal metastasis
● M	Mediastinal
● N	Supraclavicular, cervical or axillary
● O	No abdominal node metastasis
● ABC	Node stage as defined in stage II
IV	Extra lymphatic metastasis
Lung	
● L1	<3 metastases
● L2	3 metastases or more, <2 cm in diameter
● L3	3 metastases or more, one or more of which >2 cm in diameter
H+: liver metastases; Br+: brain metastases; Bo+: bone metastases	

TNM

Tx	Primary tumour cannot be assessed
T0	No evidence of primary
Tis	ITGCN (CIS)
T1	Confined to testis/epididymis, no vascular/lymphatic invasion [tumour may involve t. albuginea but not t. vaginalis]
T2	Confined to testis with vascular/lymphatic invasion, or t. vaginalis involvement
T3	Spermatic cord invasion
T4	Scrotal invasion
Nx	Cannot be assessed
N0	No regional LN
N1	Regional LN <2cm and 5 or less
N2	Regional LN 2-5cm or more than 5

N3 Regional LN >5cm diameter

Mx Cannot be assessed

M0 No mets

M1 Distant mets

M1a Non-regional LN or lung

M1b Other sites

Sx Not recorded

S1	BHCG <5000;	AFP <1000;	LDH <1.5
S2	BHCG 5000-50000;	AFP 1000-10000;	LDH 1.5-10
S3	BHCG >50000;	AFP >10000;	LDH > 10

Prognosis (International germ-cell cancer collaborative group)

Table 3 IGCCG prognostic classification of germ cell tumours of the testis		
	NSGCT	Seminoma
Good prognosis	All of: Testis or retroperitoneal primary tumours, no non-pulmonary visceral metastases (ie, lung metastases only) AFP <1000 ng/ml β-HCG <5000 mIU/ml LDH <1.5×ULN	Any primary site No non-pulmonary visceral metastases (ie, lung metastases only) Normal AFP Any β-HCG, any LDH
Intermediate prognosis	Testis or retroperitoneal primary No non-pulmonary visceral metastases and any of: AFP >1000–<10000 ng/ml β-HCG >5000–<50000 mIU/ml LDH >1.5–<10×ULN	Any primary site Non-pulmonary visceral metastases, normal AFP Any β-HCG, any LDH
Poor prognosis	Any of: Mediastinal primary site Non-pulmonary visceral metastases AFP >10000 ng/ml β-HCG >500000 mIU/l, LDH >10×ULN	No patients in this group

AFP, α-fetoprotein; β-HCG, β-human chorionic gonadotrophin; IGCCG, International Germ Cell Cancer Collaborative Group; LDH, lactate dehydrogenase; NSGCT, non-seminomatous germ cell tumour; ULN, upper limit of normal.

Sites of extragonadal GCT:

Mediastinum

Retroperitoneum

Sacrococcygeal

Perineal

Subsequent prognosis and treatment depends on assigning patients to low and high risk stage 1 disease, and good, intermediate and poor prognosis

Stage	NSGCT (%5YS)	Seminoma (%5YS)
Stage 1	95	95
Good prognosis mets	92	86
Intermediate prognosis mets	80	72
Poor prognosis mets	48	n/a

Treatment

Radical inguinal orchidectomy

Treatment, staging and prognostic information

Inguinal approach: theoretical reduction in lymphatic spread to scrotal wall; allows easy examination of testis; complete removal of cord lymphatic tissue (for subsequent RPLND)

Probably no value in clamping cord

CT chest, abdo and pelvis post-op

Tumour markers one week and two weeks post-op

Local recurrence after inguinal orchidectomy extremely rare; slightly higher after scrotal exploration (Leibovitch 1995; Kennedy 1986), but unlikely to affect survival given efficacy of chemotherapy

Stage I Seminoma

Risk of relapse 15-20% after 5 years.

32% risk with rete testis invasion & tumour > 4cm; 12% without either (Warde 2002)

Options active surveillance, post-orchidectomy RT or single-agent chemotherapy

Surveillance:

Avoids unnecessary Rx in 80%, but needs high compliance. Relapse amenable to radiotherapy in 70%. 20% of these patients require further chemoRx (overall half of patients required multi-agent chemotherapy). Relapse occurs within 2 years in 70%. Late relapse > 5 yrs in 7%.

Radiotherapy:

Traditionally dogleg from ipsilateral renal hilum to ipsilateral pelvic and local testicular nodes; 30Gy in 15 fractions over 3 weeks (T10 to L5).

Limited para-aortic field has equivalent 3-yr survival, lower morbidity and slightly higher pelvic relapse (4% vs. 3.4%) cf. dogleg (MRC testicular tumour working group; Fossa TE10 trial 1999)

Para-aortic RT: 20 Gy in 10 fractions equivalent to 30 Gy in 15 fractions at 5 years follow-up with better side-effect profile (MRC TE18; Jones 2005) Main side-effects nausea and vomiting, long term peptic ulceration and tiny increase in 2nd Ca (currently unquantified).

Single-agent chemotherapy:

Single agent carboplatin (single IV injection 7x GFR+25mg) not statistically different from adjuvant RT in preventing relapse. Both groups reduced relapse rate to 4-5% at 3 years. Slight trend to PA node relapse in chemotherapy arm.

Increased second cancers (2% vs. 0.5%) in radiotherapy arm (MRC TE19/EORTC 30982; Oliver 2005). Long term data required.

RPLND:

Relapse double that of RT when RPLND performed (Warsawski 1997). Not performed

Stage IIA/B Seminoma

Metastatic disease confined below diaphragm

Options depend on volume of nodal disease:

Low volume disease (IIA/IIB)

Very radiosensitive. Dogleg (p/a and ipsilateral iliac nodes) radical radiotherapy 30Gy in 15 fractions over 3 weeks; relapse rates 95% (IIA) and 89% (IIB). Overall survival 99% at 5 yrs

Alternatively 3 cycles of BEP associated with 5 yr overall survival of 98% with no late chemo toxicity (Garcia Del Muro 2004 – abstract only)

Trials of chemo vs. RT awaited

High volume disease (IIC – any node >5 cm)

Larger LN mets respond less well and damage due to RT higher.

Relapse-free survival after RT 35%. Overall 5YS (including salvage) 77%.

Therefore chemotherapy favoured, but commonly residual masses.

Post-chemo masses:

Usually necrotic material, but viable tumour may be present in up to 25% of masses > 3cm.

< 3cm surveillance CT

≥ 3 cm PET scanning = 80% sensitive and 100% specific viable tumour (SEMPET study De Santis 2004). Surgery very difficult for chemotherapy-treated seminoma. Consider surgical resection if CT/PET looks favourable. Alternatively salvage RT.

Stage I NSGCT

Overall relapse rate 30%

Dependent on RF:

Lymphovascular invasion

T2 +

Embryonal component

Absence of yolk sac component

No risk factors = 10-15% relapse rate

Vascular invasion alone 38%

More than one risk factor = 50%

Low risk disease - surveillance generally recommended

High risk disease – surveillance with chemo for relapse, primary chemotherapy, or RPLND

No prospective trial comparing the options in high-risk disease. Overall cure rate 99% irrespective of modality. Arguments:

Surveillance

98% patients relapse within 3 years
 Avoids unnecessary treatment in 50% with high-risk disease
 Requires high motivation and compliance
 Recommended follow-up regime intense
 Risks of radiological imaging need to be considered (figures)

Chemotherapy

Adjuvant chemotherapy BEP x2
 Relapse rates from 50% to <5%
 No contemporary trials of chemo vs. surveillance. Historical data suggest almost halving of mortality (2.6% to 1.4%) with chemo (Anglian GCGG; Oliver RT 2004) but inherent problems with retrospective data. However primary chemotherapy exposes 50% of patients to unnecessary chemotherapy with its attendant risks
 However no reported impact on fertility (Bohlen 1999)

RPLND

30% of stage I disease have micrometastases not identified on CT. RPLND offers a cure rate for these patients of 70%, obviating the need for chemotherapy
 Follow-up also much easier (infradiaphragmatic recurrences should not occur) and radiation exposure reduced.
 In experienced hands morbidity low: Retrograde ejaculation < 5%, adhesions 1%, hernia 3-5%.
 However, 70% of patients have unnecessary surgery; of the remaining 30%, 9% require adjuvant treatment in the form of chemotherapy. Thus NNT approximately 5 (very high cost given that salvage chemo so effective)

Ultimately because outcomes the same, decisions should be carefully discussed with patient. For a highly motivated, fit patient keen to avoid intervention, surveillance realistic option. Alternatively chemo relatively well tolerated in a majority of patients in UK/Europe.

Stage 1S NSGCT

Persistent tumour markers despite inguinal orchidectomy
 87% have retroperitoneal nodes if RPLND performed (Pizzocarro 1996)
 Therefore BEP x3

Stage IIA/B NSGCT

Chemotherapy is standard in UK standard but USA favour RPLND for stage IIA/B (so-called small volume disease)
 Second treatment rate irrespective of treatment is 30%
 Equivalent survival rates of 90% at 5 years
 Primary ChemoRx: Complete remission in 70%; surgery required for 30% with residual masses. therefore 30% get both treatments
 Primary RPLND: 20% inadequate resection/ unfavourable histo and 30% relapse; therefore 50% get both treatments

Advanced GCT

Good prognosis	BEP x3 (every 3 weeks)
Intermediate prognosis	BEP x 4 (q 3 wks); alternatively enrol in trial of BEP vs. BEP & paclitaxel
Poor prognosis	BEP x4; No evidence to date that high-dose chemoRx any more effective vs. standard dose. Trials ongoing (eg. EORTC 30974)

Post-chemotherapy masses

Seminoma – PET if >3cm; resection or salvage chemo if viable tumour

NSGCT - 25% of patients have post-chemotherapy masses:

40% necrosis/fibrosis

40% mature teratoma (TD)

20% residual NSGCT

~60% masses either malignant tumour or TD. TD insensitive to chemotherapy and benign growth (usually due to mucin production) can limit organ function (especially problematic in brain metastases rendered TD by chemotherapy); TD also has potential for malignant transformation. 5% risk of malignant transformation in one of the elements of TD (carcinoma, sarcoma, lymphoma/leukaemia) (Comiter 1998). **Therefore complete resection necessary.**

Malignant transformation of TD is a very poor prognostic factor.

Prognosis related to degree of stromal invasion within the resected mass rather than degree of differentiation. Contrary to common opinion, cannot definitely predict that all sites will have same histology after chemotherapy.

NB. If primary chemotherapy given for metastatic GCT without prior orchidectomy, up to 50% of testis may harbour viable tumour due to presence of blood-testis barrier. Therefore completion radical inguinal orchidectomy is required.

Salvage chemotherapy

Seminoma

Cisplatin based salvage chemoRx = 50% long-term remission

Regimens:

PEI x4 cisplatin, etoposide, ifosfamide

VeIP x4 Vinblastine, ifosfamide, cisplatin

TIP Taxol, ifosfamide, cisplatin

NSGCT

PEI x4 = long-term remission in 15-40%

Better with: testis/retroperitoneal primary; good response to primary chemo; long remission, low markers

?improvement response with gemcitabine/taxols and cisplatin

oxaliplatin has activity in truly platinum-refractory tumours

Brain metastases

At presentation - 30-40% 5YS

Recurrent disease – 2-5% 5S

CT head should be requested in patients with very high levels of BHCG at presentation or significant embryonal component

Consideration should be given to concomitant radiotherapy as results of chemo across BBB variable.

Other considerations

Radiotherapy

Major toxicities gastrointestinal (usually N&V), lethargy
 PA node RT associated with long-term risk of PUD – need gastroprotection
 Increased risk of second malignancy = 0.2% (2.6 fold increase). Usually solid in-field tumours (stomach, pancreas, kidney, bladder) – median onset 20 years. In addition risk of cardiovascular disease and hypertension (renal damage).
 No definite evidence that radiation treatment for seminoma associated with increased risk of solid tumours occurring in or adjacent to radiation field.

Chemotherapy

Bleomycin: lung fibrosis

Etoposide: acute myeloid leukaemia (increased risk 0.3%: median onset 10 yrs)

Cisplatin: ototoxicity, nephropathy, sensory neuropathy, Raynaud's

NB. Carboplatin is much less nephrotoxic – used as an alternative to cisplatin in patients with renal impairment, but small risk of bone marrow suppression.

Each cycle of BEP

Inpatient for 1 week (B + E + P)

Outpatient bleomycin for next 2 weeks

In total 9 injections of bleomycin and 3 each of etoposide and cisplatin

Carboplatin

Dose (mg) = (GFR+25) x 7

Given over one hour

Outpatient administration

Surgery for post-chemo masses

Remove all masses at every site where feasible

Very predictable response to chemo ie. if all masses fibrosis in abdomen, chest likely to be fibrosis as well. No need for resection.

Surgery 4-8 weeks after chemoRx completion. Watch out for bleomycin induced ARDS (limit by reducing inspired oxygen)

Abdomen - Removal of full lymphatic field; if necessary resect IVC/ involved kidney where possible. Chylous ascites may be problematic (Mx = paracentesis, high protein/low fat/high medium-chain TG diet + somatostatin. If fails TPN & somatostatin. If still problematic lymphangiogram and attempt surgical repair or shunt peritoneovenous shunt).

Follow-up radiation exposure

Increased risk of new malignancy with one CT = 0.2%

Follow-up - Seminoma

Table 8: Follow-up in surveillance policy

Procedure	Year				
	1	2	3	4-5	6-10
Physical examination	6 times	4 times	3 times	Twice/year	Once/year
Tumour markers	6 times	4 times	3 times	Twice/year	Once/year
Chest X-ray	6 times	4 times	3 times	Twice/year	Once/year
Abdominal CT scan	4 times	4 times	Twice	Once/year	If indicated
Abdominal ultrasound	^a	^a	Twice ^b	Once/year ^b	If indicated

Table 7: Follow-up for post-orchietomy radiotherapy or chemotherapy - stage I seminoma

Procedure	Year			
	1	2	3	4-5
Physical examination	6 times	4 times	3 times	Twice/year
Chest X-ray	6 times	4 times	3 times	Twice/year
Tumour markers	6 times	4 times	3 times	Twice/year
Abdominal CT scan	Once	Once	If indicated	If indicated
Abdominal ultrasound	Once ^a	Once ^a	Once	If indicated

Table 10: Follow-up of seminoma stage IIa-IIb after radiotherapy

Procedure	Year					
	1	2	3	4	5	>5
Physical examination	6 times	4 times	3 times	Twice	Twice	Once/year
Tumour markers	6 times	4 times	3 times	Twice	Twice	Once/year
Chest X-ray	6 times	4 times	3 times	Twice	Twice	Once/year
CT abdomen and pelvis ^a	If indicated	If indicated	If indicated	If indicated	If indicated	If indicated
CT chest ^b	If indicated	If indicated	If indicated	If indicated	If indicated	If indicated

Table 11: Follow-up of advanced NSGCT and seminoma

Procedure	Year					
	1	2	3	4	5	Thereafter
Physical examination	12 times	6 times	4 times	3 times	Twice	Once/year
Tumour markers	12 times	6 times	4 times	3 times	Twice	Once/year
Chest X-ray	12 times	6 times	4 times	3 times	Twice	Once/year
Abdominal CT ^{ab}	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated
Chest CT ^{bc}	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated
Brain CT ^d	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated

Follow-up - NSCGT

Table 5: Recommended follow-up schedule in a surveillance policy - stage I non-seminoma

Procedure	Year			
	1	2	3-5	6-10
Physical examination	Monthly	4-6 times	Twice/year	Once/year
Tumour markers	9-12 times (Monthly for the first 6 months)	4-6 times	Twice/year	Once/year
Chest X-ray	9-12 times (Monthly for the first 6 months)	4-6 times	Twice/year	Once/year
Abdominal CT scan	3-4 times	Twice	Once/year	If indicated

Table 6: Recommended follow-up schedule after retroperitoneal lymphadenectomy or adjuvant chemotherapy - stage I non-seminoma


Procedure	Year			
	1	2	3-5	6-10
Physical examination	6 times	3 times	Twice/year	Once/year ^a
Tumour markers	6 times	3 times	Twice/year	Once/year ^a
Chest X-ray	6 times	3 times	Twice/year	Once/year ^a
Abdominal CT scan	Twice	Once	If indicated ^b	If indicated
Abdominal ultrasound	Twice ^c	Twice ^c	Twice/year	Once/year

Table 11: Follow-up of advanced NSGCT and seminoma

Procedure	Year					
	1	2	3	4	5	Thereafter
Physical examination	12 times	6 times	4 times	3 times	Twice	Once/year
Tumour markers	12 times	6 times	4 times	3 times	Twice	Once/year
Chest X-ray	12 times	6 times	4 times	3 times	Twice	Once/year
Abdominal CT ^{ab}	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated
Chest CT ^{bc}	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated
Brain CT ^d	As indicated	As indicated	As indicated	As indicated	As indicated	As indicated

Appendix

Retroperitoneal Lymph Node Dissection



Landing sites

Right side	Aortocaval first Then pre-aortic and pre-caval
Left side	Para-aortic and pre-aortic

Very rare for left-sided tumours to have positive right sided nodes (<1%). Much more common for right-sided tumours to have left-sided nodes

Templates

Options include bilateral, modified right and modified left.

Nerve sparing templates designed to preserve antegrade ejaculation. Emission is controlled by T12-L3 sympathetic outflow. Most important areas for preservation is the paravertebral sympathetic chain, post-ganglionic sympathetic fibres and particularly their confluence in the midline around the origin of the IMA to form the hypogastric plexus.

Bilateral RPLND

Thoracoabdominal and transabdominal approaches

Transabdominal

Full midline


Reflection of TC and omentum onto chest

Incision along left edge of root of small bowel mesentery from DJ flexure to caecal pole

Incision continued up ascending colon to foramen of Winslow;

kocherisation of duodenum. Entire small bowel and ascending colon can

now be placed along with TC on chest wall in a bowel bag – identify and preserve SMA



Template dissection as above:

From superior aspect of renal vein on either side, along medial margins of the ureter to iliac artery on each side. Along iliac artery to aortic bifurcation

Starts at left renal vein; division of adrenal, gonadal and lumbar arteries. Anterior 'split and roll' technique for en-bloc dissection (see below)

NB. For nerve-sparing, initial anterior split OK for IVC but not for aorta






Figure 30-11 A to G. Sequentially, this diagram shows the "split and roll" technique that allows for en bloc removal of the nodal package. The lumbar vessels must be divided twice, first at the wall of the great vessels and again as they enter the foramina alongside the vertebral bodies.



Modified templates

Typically used for primary RPLND, especially left sided, and occasionally for well-demarcated unilateral disease (must proceed to complete bilateral RPLND if frozen-section positive)



Complications (25%)

- Infection, bleeding, DVT/PE, scar, hernia
- Lymphocoele
- Retrograde ejaculation/anejaculation
- Chylous ascites
- Renovascular injury/nephrectomy
- Small bowel injury/obstruction
- Death (1-3%)

Leydig-cell tumours

3% primary testicular tumours (most common interstitial tumour of testis)

3% bilateral

Bimodal age distribution; 20% kids 5-10 yrs, 80% adults 30-60yrs

A/w Klinefelter's syndrome

Yellow/brown tumour

Most small < 5cm

80% produce hormones,

Adults - typically oestrogen or FSH in adults: 30% with gynaecomastia

Children – typically virilisation due to production of testosterone (diff. diagnosis CAH)

Diagnosis: cytological atypia + lipofuscin + crystal of Reinke. Absent IHC for PLAP, AFP or BHCG, but stain positive for inhibin

Prognosis: 10% malignant [high mitoses, increased MIB-1, >5cm, vascular invasion, necrosis, extratesticular extension]

Treatment: Organ preserving surgery may be appropriate in patients who are confidently predicted to have non-GCT (ie. new gynaecomastia and hormonal abnormalities). All others = radical inguinal orchidectomy and follow-up staging investigations. In those with high chances of malignancy, RPLND recommended. Established mets poorly sensitive to chemoRx or RRT and survival poor.

Sertoli-cell tumours

1% primary testicular tumours

Most common testicular tumour in dogs!

Mean age 45 yrs

Associated with AIS & Peutz-Jeghers syndrome

Yellow/brown

Typically < 5 cm

Hormonal imbalance less common but still 30% with gynaecomastia

Negative for PLAP, AFP, BHCG, positive for inhibin and calretinin

Three subtypes:

Classic Sertoli

Large cell calcifying (syndromes eg. PJ, MEN 1 and 2, 44% bilateral)

Large cell sclerosing

Overall 10% malignant. Risk factors same as for Leydig.

20% malignancy in large-cell sclerosing subtype

Treatment: Organ preserving surgery may be appropriate in patients who are confidently predicted to have non-GCT (ie. new gynaecomastia and hormonal abnormalities). All others = radical inguinal orchidectomy. In those with high chances of malignancy, RPLND recommended. Established mets poorly sensitive to chemoRx or RRT and survival poor.

Adenomatoid tumours of epididymis

Commonest paratesticular tumour - accounts for ~30%

Typically males in 20-30s

Usually epididymis, occasionally tunical layers

Lower pole > upper pole

Epithelial cells and fibrous stroma – often vacuoles within epithelial cells

Universally benign – never been a reported case

Rx by surgical excision (exclude even rarer cases of paratesticular mass – mesothelioma and rhabdomyosarcoma)

Testicular epidermoid tumours

Testicular epidermoid cyst accounts for 1-2% testicular tumours.

Radiological features:

- Well circumscribed hypoechoic lesion
- Hyperechoic margins
- Normal surrounding parenchyma
- "onion ring appearance"

MRI- does not enhance

PRICE histological criteria (1969):

1. Cyst within testicular parenchyma
2. Lumen of cyst contains keratin
3. No teratomatous elements or adnexal structures
4. Absence of CIS
5. Absence of scar in remaining testis
6. The cyst wall should contain fibrous tissue and squamous epithelium

Treatment:

1. Radical orchidectomy if diagnostic uncertainty
2. Organ preserving surgery if two intraoperative biopsies from the cyst show no GCT and biopsy of the rest of the parenchyma shows no GCT or CIS